Details for New Drug Application (NDA): 020937
✉ Email this page to a colleague
The generic ingredient in OPTIMARK is gadoversetamide. There is one drug master file entry for this compound. Additional details are available on the gadoversetamide profile page.
Summary for 020937
Tradename: | OPTIMARK |
Applicant: | Liebel-flarsheim |
Ingredient: | gadoversetamide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1654.5MG/5ML (330.9MG/ML) | ||||
Approval Date: | Dec 8, 1999 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 3309MG/10ML (330.9MG/ML) | ||||
Approval Date: | Dec 8, 1999 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 4963.5MG/15ML (330.9MG/ML) | ||||
Approval Date: | Dec 8, 1999 | TE: | RLD: | Yes |
Expired US Patents for NDA 020937
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Liebel-flarsheim | OPTIMARK | gadoversetamide | INJECTABLE;INJECTION | 020937-003 | Dec 8, 1999 | 5,130,120 | ⤷ Subscribe |
Liebel-flarsheim | OPTIMARK | gadoversetamide | INJECTABLE;INJECTION | 020937-001 | Dec 8, 1999 | 5,130,120 | ⤷ Subscribe |
Liebel-flarsheim | OPTIMARK | gadoversetamide | INJECTABLE;INJECTION | 020937-004 | Dec 8, 1999 | 5,130,120 | ⤷ Subscribe |
Liebel-flarsheim | OPTIMARK | gadoversetamide | INJECTABLE;INJECTION | 020937-003 | Dec 8, 1999 | 5,137,711 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription